Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Bitcoin

Bitcoin’s September Showdown: Institutional Momentum Versus Seasonal Pressure

Robert Sasse by Robert Sasse
September 3, 2025
in Bitcoin, Blockchain, ETF, Market Commentary, Trading & Momentum
0
Bitcoin Stock
0
SHARES
209
VIEWS
Share on FacebookShare on Twitter

As Bitcoin enters September 2025, it faces a well-documented historical challenge. This month has traditionally been the weakest performing period for the cryptocurrency, posting average losses of -3.77%. However, a powerful new force has entered the equation: billions of dollars in institutional capital flowing through Bitcoin ETFs. This sets the stage for a compelling battle between established seasonal patterns and evolving market structure.

Institutional Inflows Defy Historical Trends

The gravitational pull of historical performance appears to have little effect on institutional appetite. On September 3 alone, BlackRock’s IBIT Bitcoin ETF recorded substantial inflows totaling $72.9 million. The collective holdings across all Bitcoin ETFs have now surpassed 1.47 million BTC, representing a significant 7% of Bitcoin’s total circulating supply.

This institutional confidence follows a period of notable pressure in August, when aggregate outflows reached $751 million across all Bitcoin ETFs. These contrasting movements highlight the inherent volatility within institutional cryptocurrency investments and help explain the price pressure witnessed in recent weeks.

On-Chain Metrics Present Mixed Signals

While ETF flows suggest growing institutional optimism, blockchain data reveals a more complex narrative. The adjusted transfer volume has declined by 13%, dropping from a monthly average of $26.7 billion to $23.2 billion. According to analysts at Glassnode, a further decline below the yearly average of $21.6 billion could signal “weakening speculative activity.”

Simultaneously, long-term Bitcoin holders are realizing profits at levels second only to previous cycle peaks. This profit-taking behavior among traditionally steadfast investors is creating additional downward pressure on prices.

Should investors sell immediately? Or is it worth buying Bitcoin?

Confronting the September Curse

Historical data presents a clear pattern: Bitcoin has declined in value during September in 9 of the past 14 years, with average losses reaching 12%. This consistent underperformance has established September as a period of heightened investor anxiety.

The 2025 landscape differs significantly from previous years. The emergence of robust institutional infrastructure, increasing regulatory clarity, and evolving market dynamics may collectively counteract—or potentially override—these traditional seasonal weaknesses.

Critical Technical Levels in Focus

From a technical analysis perspective, Bitcoin approaches a decisive juncture. The support zone between $108,000 and $110,000 represents a critical foundation for future price action. A decisive breakout above $118,000 could signal renewed bullish momentum, while a breakdown below current support levels might test the psychologically significant $100,000 threshold.

Despite prevailing uncertainty, trading volume remains robust at $143 billion, indicating healthy market liquidity. The combination of sustained institutional participation and ongoing retail engagement underscores Bitcoin’s broad market appeal.

The coming weeks will determine whether Bitcoin’s evolving fundamental structure can overcome its historical seasonal tendencies, or if the September effect will persist even in this new era of institutional adoption.

Ad

Bitcoin Stock: Buy or Sell?! New Bitcoin Analysis from February 8 delivers the answer:

The latest Bitcoin figures speak for themselves: Urgent action needed for Bitcoin investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Bitcoin: Buy or sell? Read more here...

Tags: Bitcoin
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Communications Stock
Industrial

The Race to Rewire: Fiber Optics Reshape the Telecom Landscape

February 7, 2026
Hbt Financial Stock
Analysis

HBT Financial Stock Surges as Strategic Acquisition Nears Completion

February 7, 2026
Next Post
DroneShield Stock

DroneShield Shares: A Growth Story Taking Flight Despite Recent Pullback

SAP Stock

SAP's $20 Billion Bet on European Digital Sovereignty

Thyssenkrupp Stock

European Steel Giant Faces Existential Threat from Subsidized Imports

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com